BRAF and MEK Inhibitor–Induced Cardiotoxicity in Metastatic Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting
Acta Oncol 2021 Oct 19;[EPub Ahead of Print], S Pedersen, KO Larsen, AH Christensen, IM Svane, B Zerahn, E EllebaekFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.